Union Health Ministry Limits Stem‑Cell Therapy for Autism to Approved Clinical Trials – Advisory Post SC Verdict

The Union Health Ministry issued an advisory on 16 September 2026 directing all States and Union Territories to limit stem cell therapy to conditions expressly approved by the Ministry, and to confine its use for ASD to duly approved clinical trials. Key Developments The advisory reiterates the regulatory framework set by the Clinical Establishments (Registration and Regulation) Act, 2010 , following the Supreme Court judgment in Yash Charitable Trust & Ors. v. Union of India & Ors. on 30 January 2026 . For ASD, any stem‑cell intervention must be administered only under the National Guidelines for Stem Cell Research, 2017 , which require approval for clinical trials. The ICMR review concluded that current evidence does not favour stem‑cell therapy over behavioural and supportive therapies for ASD. The NMC issued a separate advisory on 5 September 2026 , stating that unauthorised use, promotion or advertisement of stem‑cell therapy constitutes professional misconduct. Important Facts States and UTs must circulate the Supreme Court directions to all regulatory bodies, government and private clinical establishments involved in stem‑cell work. Non‑compliance may attract penalties under Regulation 7.22 of the erstwhile Indian Medical Council Regulations, 2002, and Sections 32 and 40 of the Clinical Establishments Act, including cancellation of registration. Professional misconduct findings by State Medical Councils can lead to disciplinary action as per NMC provisions. UPSC Relevance This development touches upon several UPSC syllabus areas: the role of the Union Health Ministry and National Medical Commission in health governance (GS2); the legal authority of the Supreme Court in enforcing regulatory compliance (GS2); and the scientific‑ethical considerations of emerging medical technologies like stem cell therapy (GS1). Aspirants should understand how policy, law, and evidence‑based medicine intersect in India’s health sector. Way Forward States should set up monitoring mechanisms to ensure that only approved stem‑cell trials for ASD are conducted. Medical colleges and research institutions must align their protocols with the 2017 guidelines and seek necessary clearances. Public awareness campaigns can help curb unregulated commercial promotion, protecting vulnerable patients and upholding ethical standards.